» Articles » PMID: 23227088

Epithelial-to-mesenchymal Transition in Pancreatic Ductal Adenocarcinoma and Pancreatic Tumor Cell Lines: the Role of Neutrophils and Neutrophil-derived Elastase

Overview
Date 2012 Dec 11
PMID 23227088
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is frequently associated with fibrosis and a prominent inflammatory infiltrate in the desmoplastic stroma. Moreover, in PDAC, an epithelial-to-mesenchymal transition (EMT) is observed. To explore a possible connection between the infiltrating cells, particularly the polymorphonuclear neutrophils (PMN) and the tumor cell transition, biopsies of patients with PDAC (n = 115) were analysed with regard to PMN infiltration and nuclear expression of β-catenin and of ZEB1, well-established indicators of EMT. In biopsies with a dense PMN infiltrate, a nuclear accumulation of β-catenin and of ZEB1 was observed. To address the question whether PMN could induce EMT, they were isolated from healthy donors and were cocultivated with pancreatic tumor cells grown as monolayers. Rapid dyshesion of the tumor cells was seen, most likely due to an elastase-mediated degradation of E-cadherin. In parallel, the transcription factor TWIST was upregulated, β-catenin translocated into the nucleus, ZEB1 appeared in the nucleus, and keratins were downregulated. EMT was also induced when the tumor cells were grown under conditions preventing attachment to the culture plates. Here, also in the absence of elastase, E-cadherin was downmodulated. PMN as well as prevention of adhesion induced EMT also in liver cancer cell line. In conclusion, PMN via elastase induce EMT in vitro, most likely due to the loss of cell-to-cell contact. Because in pancreatic cancers the transition to a mesenchymal phenotype coincides with the PMN infiltrate, a contribution of the inflammatory response to the induction of EMT and-by implication-to tumor progression is possible.

Citing Articles

Neutrophils in Cancer immunotherapy: friends or foes?.

Huang X, Nepovimova E, Adam V, Sivak L, Heger Z, Valko M Mol Cancer. 2024; 23(1):107.

PMID: 38760815 PMC: 11102125. DOI: 10.1186/s12943-024-02004-z.


Targeting neutrophil elastase is a promising direction for future cancer treatment.

Jia W, Mao Y, Luo Q, Wu J, Guan Q Discov Oncol. 2024; 15(1):167.

PMID: 38750338 PMC: 11096153. DOI: 10.1007/s12672-024-01010-3.


Prognostic impact of tumor-associated neutrophils in breast cancer.

Kakumoto A, Jamiyan T, Kuroda H, Harada O, Yamaguchi-Isochi T, Baba S Int J Clin Exp Pathol. 2024; 17(3):51-62.

PMID: 38577697 PMC: 10988089. DOI: 10.62347/JQDQ1527.


The Interplay between T Cells and Cancer: The Basis of Immunotherapy.

Chen C, Liu X, Chang C, Wang H, Wang R Genes (Basel). 2023; 14(5).

PMID: 37239368 PMC: 10218245. DOI: 10.3390/genes14051008.


Pterostilbene supresses inflammation-induced melanoma metastasis by impeding neutrophil elastase-mediated thrombospondin-1 degradation.

Su D, Xu S, Ji K, Xu H, Li Y, Zhang Z Chin Herb Med. 2023; 15(1):94-101.

PMID: 36875428 PMC: 9975619. DOI: 10.1016/j.chmed.2022.08.004.


References
1.
Gaida M, Welsch T, Herpel E, Tschaharganeh D, Fischer L, Schirmacher P . MHC class II expression in pancreatic tumors: a link to intratumoral inflammation. Virchows Arch. 2011; 460(1):47-60. DOI: 10.1007/s00428-011-1175-x. View

2.
von Burstin J, Eser S, Paul M, Seidler B, Brandl M, Messer M . E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009; 137(1):361-71, 371.e1-5. DOI: 10.1053/j.gastro.2009.04.004. View

3.
De Wever O, Lapeire L, De Boeck A, Hendrix A . Cellular and molecular mechanisms of cancer cell invasion. Verh K Acad Geneeskd Belg. 2011; 72(5-6):309-26. View

4.
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi A, Kong D . Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 2010; 8(1):27-33. DOI: 10.1038/nrgastro.2010.188. View

5.
Maier H, Wirth T, Beug H . Epithelial-mesenchymal transition in pancreatic carcinoma. Cancers (Basel). 2013; 2(4):2058-83. PMC: 3840444. DOI: 10.3390/cancers2042058. View